ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate | 1313515-96-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate
• 英文别名: Ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazole-5-carboxylate
• CAS: 1313515-96-6
• 化学式: C₁₇H₁₈BrFN₂O₄
• 分子量: 413.243
• InChiKey: FITXWXYMTSFCOO-UHFFFAOYSA-N

物化性质

• 沸点：
  520.7±50.0 °C(Predicted)
• 密度：
  1.465±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  64.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate 在 ammonium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以91%的产率得到3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide
  参考文献：
  名称：

  Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia

  摘要：

  The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.

  DOI：

  10.1021/jm200319u
• 作为产物：
  描述：

  2-溴-5-氟苯酚 在 偶氮二甲酸二叔丁酯 、 potassium hydrogencarbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 36.0h， 生成 ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate
  参考文献：
  名称：

  Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia

  摘要：

  The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.

  DOI：

  10.1021/jm200319u

文献信息

• J. Med. Chem. 2011, 54, 5082-5096
  作者：

  DOI：——

  日期：——
• Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia
  作者：Renata M. Oballa、Liette Belair、W. Cameron Black、Kelly Bleasby、Chi Chung Chan、Carole Desroches、Xiaobing Du、Robert Gordon、Jocelyne Guay、Sebastien Guiral、Michael J. Hafey、Emelie Hamelin、Zheng Huang、Brian Kennedy、Nicolas Lachance、France Landry、Chun Sing Li、Joseph Mancini、Denis Normandin、Alessandro Pocai、David A. Powell、Yeeman K. Ramtohul、Kathryn Skorey、Dan Sørensen、Wayne Sturkenboom、Angela Styhler、Deena M. Waddleton、Hao Wang、Simon Wong、Lijing Xu、Lei Zhang

  DOI：10.1021/jm200319u

  日期：2011.7.28

  The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.